We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




PCR-Based POC Molecular Diagnostic System to Combat Infectious Diseases

By LabMedica International staff writers
Posted on 28 Jan 2025

Chlamydia, Gonorrhea, and Trichomoniasis are among the most common sexually transmitted infections (STIs) worldwide, with an estimated 129 million, 82 million, and 151 million cases respectively reported in 2020. More...

Detecting these infections accurately typically relies on PCR-based molecular diagnostics, which have traditionally been carried out in centralized laboratories that require significant infrastructure. This setup limits accessibility in low- and middle-income countries where medical resources are often scarce. Now, a point-of-care (POC) molecular diagnostic device integrates all processes into a single, compact instrument to provide a rapid, reliable solution for detecting STIs, enabling timely interventions in resource-constrained settings.

Kryptos Biotechnologies (Hayward, CA, USA) is advancing its proprietary PCR-based POC molecular diagnostic system, the KUICK System, designed to combat infectious diseases and enhance healthcare outcomes globally. Kryptos is collaborating with Osang Healthcare (Gyeonggi-do, Republic of Korea) for a research project that will focus on developing molecular diagnostic reagents for STIs. The aim of this collaboration is to create a multiplex STI diagnostic test capable of detecting Chlamydia, Gonorrhea, and Trichomoniasis in under 30 minutes from a single patient sample.

As part of this collaboration, Osang will develop real-time PCR reagents, while Kryptos will focus on optimizing the KUICK System, particularly its innovative cartridge with integrated sample preparation chemistries. The system’s performance is also being improved to ensure reliability in diverse healthcare settings. In developed countries, the device will allow smaller clinics to offer accurate, same-day results, thereby significantly improving patient care.

“Our proprietary photothermal heating technology enables the KUICK System to meet diverse market demands for speed, accuracy, cost-efficiency, and portability,” said Dr. Jun Ho Son, CTO of Kryptos Biotechnologies and principal investigator of the project. “We are committed to ensuring this product makes a meaningful impact on healthcare environments, particularly in low- and middle-income countries.”

Related Links:
Kryptos Biotechnologies 
Osang Healthcare


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.